Health Care • Biotechnology: Pharmaceutical Preparations
$1.44 ▼ -0.07
(-4.64%)
MKT CAP: $31.5M • VOL: 955.9K
52W L $1 52W H $17
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
AARD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$62.7M | -$22.8M |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$57.6M | -$20.6M |
| EBITDA (Normalized) | -$62.6M | -$22.7M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$54.2M | -$18.1M |
| Capital Expenditures (CapEx) | $95.0K | $109.0K |
| Free Cash Flow (FCF) | -$54.3M | -$18.2M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $47.1M | $61.6M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $106.6M | -$54.6M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AARD.